Irritable Bowel Syndrome Clinical Trial
| Verified date | February 2013 |
| Source | Karolinska Institutet |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | Sweden: Regional Ethical Review Board |
| Study type | Interventional |
Patients with a diagnosis of irritable bowel syndrome (IBS) are recruited by self-referral. They are randomized to two 10 weeks of internet-delivered cognitive behavioral programs. Both programs include mindfulness training, education about how excessive avoidant and control behaviors maintain IBS symptoms, and changing of these behaviors to live a richer life. One of the programs also includes instructions on how to perform systematic exposure. The hypothesis of the study is while both groups will show improvement in terms of IBS symptom severity and quality of life, the addition of systematic exposure will lead to more improvement in symptoms.
| Status | Completed |
| Enrollment | 311 |
| Est. completion date | December 2012 |
| Est. primary completion date | December 2012 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - Fluency in Swedish - IBS-diagnosis established by physician - Fulfillment of Rome III criteria for IBS Exclusion Criteria: - Diarrhea predominance with no colonoscopy performed - Blood in stool without benign medical explanation - Rapid weight loss without benign medical explanation - Ongoing alcohol or drug abuse - Suicidal ideation |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| n/a | |||
| Lead Sponsor | Collaborator |
|---|---|
| Karolinska Institutet |
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Gastrointestinal symptom rating scale | 1 week before randomization | No | |
| Primary | Gastrointestinal symptom rating scale | 10 weeks after randomization (i.e. after conclusion of treatment) | No | |
| Primary | Gastrointestinal symptom rating scale | 36 weeks after randomization (i.e. 6 months after conclusion of treatment) | No | |
| Secondary | Irritable Bowel Syndrome Quality of Life Instrument (IBS-QOL) | 1 week before randomization | No | |
| Secondary | Irritable Bowel Syndrome Quality of Life Instrument (IBS-QOL) | 10 weeks after randomization (i.e. after conclusion of treatment) | No | |
| Secondary | Irritable Bowel Syndrome Quality of Life Instrument (IBS-QOL) | 36 weeks after randomization (i.e. 6 months after conclusion of treatment) | No | |
| Secondary | Visceral Sensitivity Index (VSI) | 1 week before randomization | No | |
| Secondary | Visceral Sensitivity Index (VSI) | 10 weeks after randomization (i.e. after conclusion of treatment) | No | |
| Secondary | Visceral Sensitivity Index (VSI) | 36 weeks after randomization (i.e. 6 months after conclusion of treatment) | No |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03720314 -
Microbiota Profiling in IBS
|
||
| Recruiting |
NCT06166563 -
Exercise, Irritable Bowel Syndrome and Fibromyalgia
|
N/A | |
| Completed |
NCT05213910 -
Study of a Management Strategy of Functional Bowel Disordes Related to Irritable Bowel Syndrome (IBS) With a Mixture of 8 Microbiotic Strains
|
N/A | |
| Recruiting |
NCT05985018 -
Traditional Dietary Advice Vs. Mediterranean Diet in IBS
|
N/A | |
| Completed |
NCT04486469 -
Efficacy of Physiotherapy Techniques on Irritable Bowel Syndrome (IBS). Pilot Study.
|
N/A | |
| Completed |
NCT06407609 -
Positive Outcomes of the Supplementation With Lecithin-based Delivery Form of Curcuma Longa and of Boswellia Serrata in IBS
|
N/A | |
| Completed |
NCT04656730 -
Effect of STW5 (Iberogast ®) and STW5-II (Iberogast N®) on Transit and Tolerance of Intestinal Gas
|
Phase 4 | |
| Completed |
NCT04145856 -
Combination of Alverine-simeticone and i3.1 Probiotic in IBS-D and IBS-M in Mexico
|
Phase 4 | |
| Recruiting |
NCT04138225 -
The Ecological Role of Yeasts in the Human Gut
|
||
| Active, not recruiting |
NCT03586622 -
One Year Home Monitoring and Treatment of IBS Patients
|
N/A | |
| Completed |
NCT05207618 -
Utility of the Administration of Chesnut and Quebracho Extract for Irritable Bowel Syndrome Diarrhea Predominant
|
N/A | |
| Not yet recruiting |
NCT06369753 -
Visible Abdominal Distension
|
N/A | |
| Not yet recruiting |
NCT05157867 -
In Vivo Effects of Amylase Trypsin Inhibitors
|
N/A | |
| Not yet recruiting |
NCT05100719 -
The Role of Irritable Bowel Syndrome in Lactose Intolerance (LION)
|
N/A | |
| Recruiting |
NCT05001997 -
Effects of Lactose-free Dairy Products on Athletes With Irritable Bowel Syndrome
|
N/A | |
| Recruiting |
NCT02953171 -
Probiotics in the Treatment of Irritable Bowel Syndrome
|
N/A | |
| Completed |
NCT02977975 -
Lacto-fermented Sauerkraut in the Treatment of Irritable Bowel Syndrome
|
N/A | |
| Completed |
NCT03266068 -
Epidemiology and Pathophysiology of Post-Infectious Functional GI Disorders
|
||
| Completed |
NCT03318614 -
Bifidobacterium Infantis M-63 Improves Mental Health in Irritable Bowel Syndrome Developed After a Major Flood Disaster
|
Phase 2/Phase 3 | |
| Completed |
NCT02980406 -
The Role of FODMAPs in Upper GI Effects, Colonic Motor Activity and Gut-brain Signaling at the Behavioral Level
|
N/A |